Judge's ruling allows Sandoz to begin marketing its biosimilar Zarxio
A judge for the US Court of Appeals for the Federal Circuit declined an Amgen motion for a temporary injunction that would have prevented the launch of the first biosimilar in the US—Novartis's Zarxio—which is a biologic copy of Amgen's oncology treatment Neupogen.
The court's ruling allows Sandoz, Novartis's generic drug arm, to begin marketing Zarxio. The court had ruled in favor of Novartis in July, which led Amgen to appeal.
Biosimilar versions of biologic drugs are expected to help lower costs, in part by having lower price tags as well as creating more competitive markets.
Neither Amgen nor Sandoz immediately responded to requests for comment.
Neupogen reported sales of $1 billion in 2013.
MM&M's coverage of the road to approval for the first US biosimilar: